United States: FDA Clarifies Its Position On Several Compounding Issues In New Draft Guidance Documents

On April 15, 2016, the U.S. Food and Drug Administration (FDA) announced the release of three new draft guidance documents on drug compounding under Sections 503A and 503B of the Food, Drug, and Cosmetic Act (FDCA).1 These draft guidance documents cover:

Through these topics, the documents provide further insight into FDA's current position on certain areas of drug compounding.

Prescription Requirement Under Section 503A

In its draft guidance on Section 503A's prescription requirement, FDA provided insight into its approach to enforcement of Section 503A's requirement that compounding eligible for certain FDCA exemptions under 503A may occur only pursuant to a valid prescription or under very limited circumstances prior to receipt of such a prescription. While FDA acknowledged the need for some physicians to maintain office supplies of compounded drugs, it established a relatively strict approach to anticipatory compounding, including compounding for office use. FDA noted that under Section 503A(a)(2) of the FDCA, licensed pharmacists and physicians may compound prior to receipt of a patient-specific prescription only if such compounding is in limited quantity and based on a history of receiving valid prescription orders for the compounded drug within the context of an established relationship with the prescribing practitioner.

FDA declared that it would not "consider a compounder to have exceeded the limited quantity condition" as long as it holds no more than a 30-day supply of a particular compounded drug in order to fill valid prescriptions it receives later. The compounder must determine what constitutes a 30-day supply based on the maximum amount of a given product for which it received patient-specific prescriptions in a 30-day period during the previous year. If these requirements are met, FDA will not try to determine whether the compounder actually expected to receive a prescription for a particular patient or prescriber prior to compounding the drug product. However, FDA stated that if a hospital, clinic or other medical office wishes to store compounded products in excess of the limited quantities described above, it must obtain such compounded drugs from a registered outsourcing facility compliant with Section 503B.

Hospital and Health System Compounding

In its draft guidance on hospital and health system compounding, FDA recognized the need of hospitals to maintain supplies of certain compounded drugs in anticipation of immediate patient needs, but reiterated that compounding under Section 503A requires a patient-specific prescription. Nonetheless, FDA stated that it does not intend to take enforcement actions against hospital pharmacies that distribute compounded drugs without a patient-specific prescription, provided that all of the following conditions are met:

  1. The hospital pharmacy distributes the compounded products only to facilities under common ownership and control and that are located within one mile of the compounding pharmacy;
  2. The drugs will be administered only within the health facility, pursuant to a patient-specific prescription; and
  3. The pharmacy otherwise complies with all of the requirements of Section 503A in compounding the drug.

If a hospital system wishes to have one pharmacy distribute compounded drugs without a patient prescription to affiliated hospitals and practices beyond the one-mile radius, the pharmacy must register with FDA as an outsourcing facility. Thus, FDA's new draft guidance tightly limits the ability of large hospital systems to centralize their compounding activities without being required to register with FDA and comply with the requirements of 503B.

Facility Definition Under Section 503B of the FDCA

Section 503B of the FDCA created a new category of compounding facilities called outsourcing facilities. Registered outsourcing facilities, defined in part as "a facility at one geographic location or address," may compound drugs without patient prescriptions while also qualifying for exemptions from the FDCA's new drug approval and adequate directions for use labeling requirements. Such facilities must, however, comply with certain current Good Manufacturing Practice (cGMP) requirements.2 The recently released draft guidance clarifies FDA's understanding of "facility" under Section 503B and its position on whether a registered 503B outsourcing facility may also conduct other types of compounding activities in separate areas of the same premises.

As discussed in an earlier Duane Morris Alert, FDA has previously explained that a facility should register as an outsourcing facility only if all of its compounded drugs will be compounded in compliance with Section 503B. In the new draft guidance, FDA explains that it "considers all activities, equipment, appurtenances, and materials part of a [facility at one geographic location or address] if they are related to human drug compounding under the supervision of the facility's management at the same street address, or in the same building, or in buildings located in close proximity to one another." Thus, although an outsourcing facility can compound pursuant to a patient prescription, it cannot also compound drugs under Section 503A of the FDCA3 even if the areas devoted to the two standards for compounding are segregated from one another. Among FDA's concerns are that housing 503A and 503B compounding activities in the same building or facility could lead to the appearance that all drugs compounding at the facility comply with the purportedly higher standards of Section 503B, that comingling of products and activities could lead to confusion as to which standards apply and that it may be impossible to distinguish between the drugs compounded under 503A and those compounded under 503B.

In contrast, FDA will allow compounding under Section 503B to occur at a facility that also engages in "conventional" drug manufacturing because all activities at such facilities would be required to comply with cGMPs. Further, it is much easier to distinguish between compounded and manufactured drugs because of differing approval and labeling requirements, such as the requirement that compounded drug labels include the statement: "This is a compounded drug."


FDA is accepting public comments on the three draft guidance documents through July 18, 2016.4 Comments may be submitted electronically at http://www.regulations.gov or in writing to the FDA Division of Dockets Management. Further details on the procedure for submitting comments on the respective draft guidance documents are provided in the Federal Register as part of FDA's notice for each document.5 Stakeholders with concerns about FDA's newly asserted positions should consider submitting comments to FDA.


[1] Official notices for each of the draft guidance documents were published in the Federal Register on April 18, 2016.

[2] Although FDA issued interim guidance as to its cGMP expectations for outsourcing facilities on July 2, 2014, (discussed in a previous Duane Morris Alert), FDA has not yet finalized this guidance.

[3] Section 503A of the FDCA governs most compounding pursuant to patient-specific prescriptions but does not require compliance with cGMPs.

[4] For the draft guidance on the Prescription Requirement Under 503A, comments on information collection issues under the Paperwork Reduction Act of 1995 must be submitted by May 18, 2016.

[5] See 81 Fed. Reg. 22610 (Hospital and Health System Compounding); 81 Fed. Reg. 22611 (Facility Definition Under 503A); and 81 Fed. Reg. 22617 (Prescription Requirement Under 503A).

If you have any questions about this Alert or would like more information, please contact Rachael G. Pontikes, Alison T. Rosenblum, any of the attorneys in our Pharmaceutical, Medical Device, Pharmacy and Food industry group or the attorney in the firm with whom you are regularly in contact.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions